Press release
Dec 20, 2021

Sosei Heptares to Receive Milestone from GSK as GPR35 Agonist Partnership Advances

GPR35 is a genetically validated target for inflammatory bowel disease and other gastrointestinal immune disorders


Tokyo, Japan and Cambridge, UK, 20 December 2021 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, has been recently notified by its partner GSK that a milestone has been reached under their 2020 Global Collaboration and License Agreement to discover and develop selective oral small molecule agonists of GPR35 as potential treatments for immune disorders of the digestive system.

The £5 million milestone payment (~US$6.7 million at current FX rates) will be recognized as revenue in the fourth quarter of the financial year ending December 31, 2021

GPR35 is an important orphan GPCR with genetic association to inflammatory bowel disease (IBD) and other gastrointestinal immune disorders, for which there remains significant unmet need for millions of sufferers worldwide.


About the agreement with GSK

Sosei Heptares and GSK entered into a Global Collaboration and License Agreement in December 2020, under which GSK licensed global rights to a portfolio of GPR35 agonists designed by Sosei Heptares using its StaR® technology and structure-based drug design (SBDD) platform and supported by strong translational science investment in gastrointestinal biology. Sosei Heptares and GSK are jointly conducting the research and early preclinical development phases, and GSK will lead clinical development, manufacturing and commercialization. Further details of the agreement can be found by clicking here.